Barely Significant
← all excerpts

Immune checkpoint inhibitors as first line in advanced melanoma: Evaluating progression-free survival based on reconstructed individual patient data.

Cancer Med · 2023 · PMC9939083 · PMID 35920297

Europe PMCDOI
1
hedged sentence
0.0500
closest p · 1.0× alpha
0.0500
boldest claim

The sentences

did not reach statistical significancep > 0.05actually significant
the two patient groups pooled from RELATIVITY‐047 and Checkmate ‐067 trials), but the difference did not reach statistical significance (HR, 1.20; 95% CI, 0.95 to 1.51; p > 0.05).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.